Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 12/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091726 | 1.00 | RAB9A (0.44) | RAB9ANPC1ABL1MEN1KMT2A | |
| SCHEMBL23091720 | 0.83 | ABL1 (0.46) | ABL1ALDH1A1TRPV1 | |
| SCHEMBL29687463 | 0.83 | ABL1 (0.46) | ABL1ALDH1A1TRPV1 | |
| SCHEMBL29687481 | 0.82 | ABL1 (0.45) | ABL1ALDH1A1TRPV1 | |
| SCHEMBL23091728 | 0.82 | ABL1 (0.45) | ABL1ALDH1A1TRPV1 | |
| SCHEMBL23091691 | 0.82 | RAB9A (0.53) | RAB9ANPC1ABL1MEN1KMT2A | |
| SCHEMBL29687405 | 0.82 | RAB9A (0.53) | RAB9ANPC1ABL1MEN1KMT2A | |
| SCHEMBL23091719 | 0.81 | RAB9A (0.50) | RAB9ANPC1ABL1MEN1KMT2A | |
| SCHEMBL23091745 | 0.81 | NPC1 (0.47) | RAB9ANPC1ABL1MEN1KMT2A | |
| SCHEMBL29687121 | 0.81 | NPC1 (0.47) | RAB9ANPC1ABL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | claimed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | RAB9A 1661/4885NPC1 333/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.